SCHEMBL4118152

SCHEMBL4118152

CCOc1ccc(NC(=O)Nc2ccc(Cl)c(C(F)(F)F)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.72
ALDH1A1 P00352 1/20 0.72
MAPT P10636 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
KDR P35968 7/20 0.70
CA7 P43166 3/20 0.65
CA9 Q16790 3/20 0.65
CA1 P00915 2/20 0.65
CA2 P00918 2/20 0.65
BRAF P15056 3/20 0.62
MAPK14 Q16539 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
PAX8 Q06710 1/20 0.62
CDK8 P49336 2/20 0.62
RAF1 P04049 6/20 0.62
RET P07949 2/20 0.60
PLK4 O00444 1/20 0.60
CIT O14578 1/20 0.60
AURKA O14965 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12319881 0.86 KDR (0.76) LMNAMAPTSMN1; SMN2KDRCA7
SCHEMBL26077943 0.85 KDR (0.67) LMNAALDH1A1MAPTSMN1; SMN2KDR
SCHEMBL4117940 0.84 MAPT (0.66) LMNAALDH1A1MAPTSMN1; SMN2CA9
SCHEMBL118026 0.84 KDR (1.00) KDRCA7CA9CA1CA2
SCHEMBL29364392 0.84 KDR (1.00) KDRCA7CA9CA1CA2
SCHEMBL13945707 0.84 KDR (0.72) KDRCA7CA9CA1CA2
SCHEMBL3790500 0.83 KDR (0.64) KDRCA7CA9CA1CA2
SCHEMBL12310641 0.83 KDR (0.76) LMNAALDH1A1MAPTKDRCA7
SCHEMBL28901340 0.83 KDR (0.76) KDRCA7CA9CA1CA2
SCHEMBL16628055 0.83 RAF1 (0.63) KDRCA7CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 LMNA 4283/4885ALDH1A1 994/4885MAPT 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.